{"filings":[{"id":1038477,"accession_number":"0001493152-26-028610","cik":1053369,"company_name":"ELITE PHARMACEUTICALS INC /NV/","ticker":"ELTP","form_type":"8-K","filed_at":"2026-06-15T11:02:38+00:00","items":["7.01","9.01"],"status":"ready","headline":"Elite Pharmaceuticals reports positive bioequivalence for undisclosed anticonvulsant generic drug","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Pivotal BE study successful; generic product bioequivalent to branded anticonvulsant under fasting conditions.","IQVIA reports $840M combined branded and generic sales for the 12 months ending April 2026.","Elite to compile data and file ANDA with FDA; no specific timeline provided.","Study was open-label, randomized, single-dose crossover in healthy adult subjects."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":369302084.06008106,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":759239,"accession_number":"0001493152-26-026519","cik":1053369,"company_name":"ELITE PHARMACEUTICALS INC /NV/","ticker":"ELTP","form_type":"8-K","filed_at":"2026-06-01T11:00:24+00:00","items":["7.01","9.01"],"status":"ready","headline":"Elite Pharmaceuticals files ANDA for generic anticoagulant; $26B brand market, no generic available","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["ANDA submitted to FDA for generic version of an undisclosed anticoagulant drug product.","IQVIA reports branded product sales of $26 billion for twelve months ending March 2026.","No generic product currently on market; brand has unexpired patents and exclusivity in FDA Orange Book.","FDA approval and commercialization subject to successful filing, approval, and addressing patents.","Elite expands pipeline into high-value anticoagulant market; no timeline for launch provided."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":369302084.06008106,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":90939,"accession_number":"0001493152-26-014813","cik":1053369,"company_name":"ELITE PHARMACEUTICALS INC /NV/","ticker":"ELTP","form_type":"8-K","filed_at":"2026-04-02T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Elite Pharmaceuticals launches generic methadone tablets; addresses $22M market","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Launched generic methadone HCl 5 mg and 10 mg tablets under Elite Laboratories label.","Product indicated for severe persistent pain and opioid addiction detoxification/maintenance treatment.","Annual retail sales for brand and generic methadone tablets approx. $22M (IQVIA 2025 data).","Company operates a cGMP and DEA-registered R&D and manufacturing facility in Northvale, NJ."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":369302084.06008106,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":100794,"accession_number":"0001493152-26-007190","cik":1053369,"company_name":"ELITE PHARMACEUTICALS INC /NV/","ticker":"ELTP","form_type":"8-K","filed_at":"2026-02-17T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"Elite Pharma Q3 FY2026 revenue up 120% to $31.6M; net income $18.6M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $31.6M, +120% YoY; income from operations $9.0M, +721% YoY.","Net income $18.6M for three months ended Dec 31, 2025.","Growth driven by lisdexamfetamine and naltrexone product launches after prior year comparable period.","Conference call Feb 18, 2026 at 11:30 AM EST; questions due by Feb 17 evening."],"consensus_eps_estimate":null,"consensus_eps_actual":0.02,"consensus_revenue_estimate":null,"consensus_revenue_actual":108122052.0,"consensus_period":"2026-Q3","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":369302084.06008106,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":100793,"accession_number":"0001493152-26-006213","cik":1053369,"company_name":"ELITE PHARMACEUTICALS INC /NV/","ticker":"ELTP","form_type":"8-K","filed_at":"2026-02-11T23:59:59+00:00","items":["7.01","2.02","9.01"],"status":"ready","headline":"Elite Pharmaceuticals to release Q3 FY2026 results Feb 17, host call Feb 18","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Q3 FY2026 financial results will be released on Tuesday, February 17, 2026.","Conference call on Wednesday, February 18, 2026 at 11:30 AM EST.","Dial-in: 1-800-346-7359 (domestic), 1-973-528-0008 (international), conference code 98840.","Stockholders may submit general questions by 5 PM EST Feb 16; financial questions by 7 PM EST Feb 17.","Questions can be emailed to dianne@elitepharma.com."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.25,"market_cap_usd":369302084.06008106,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":117097,"accession_number":"0001493152-25-023629","cik":1053369,"company_name":"ELITE PHARMACEUTICALS INC /NV/","ticker":"ELTP","form_type":"8-K","filed_at":"2025-11-14T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"Elite Pharma Q2 FY2026 revenue $36.3M (+92% YoY); operating income $8.2M (+136% YoY)","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Consolidated revenue $36.3M for quarter ended Sept 30, 2025, up $17.4M or 92% vs prior year.","Income from operations $8.2M, up $4.7M or 136% YoY.","Growth driven by lisdexamfetamine product launches and strong Elite label product lines.","Conference call scheduled for Monday, Nov 17, 2025 at 11:30 AM EST."],"consensus_eps_estimate":null,"consensus_eps_actual":0.01,"consensus_revenue_estimate":null,"consensus_revenue_actual":76532801.0,"consensus_period":"2026-Q2","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":369302084.06008106,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":117096,"accession_number":"0001493152-25-021717","cik":1053369,"company_name":"ELITE PHARMACEUTICALS INC /NV/","ticker":"ELTP","form_type":"8-K","filed_at":"2025-11-12T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Elite Pharmaceuticals receives FDA approval for generic Requip XL (ropinirole ER) tablets","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["FDA approved ANDA for generic Requip XL (Ropinirole Extended-Release Tablets USP) in 2,4,6,8,12 mg strengths.","Product indicated for Parkinson's disease; will be marketed under Elite Laboratories label.","IQVIA data: U.S. branded & generic sales of $10M for 12 months ending September 2025.","Approval enables Elite to compete in the ropinirole ER tablet market."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":369302084.06008106,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":117094,"accession_number":"0001493152-25-022013","cik":1053369,"company_name":"ELITE PHARMACEUTICALS INC /NV/","ticker":"ELTP","form_type":"8-K/A","filed_at":"2025-11-12T23:59:59+00:00","items":["7.01","2.02","9.01"],"status":"ready","headline":"Elite Pharmaceuticals Corrects Conference Call Date for Q2 Fiscal 2026 Results","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q2 FY2026 financial results (ended Sept 30, 2025) to be released on Friday, November 14, 2025.","Conference call scheduled for Monday, November 17, 2025 at 11:30 AM EST to discuss results and provide update.","Form 8-K/A amends prior filing solely to correct the conference call date in Item 7.01.","Dial-in: 1-800-346-7359 (domestic) or 1-973-528-0008 (international); conference ID 98840.","Stockholder questions due by 5:00 PM EST on Nov 13 (general) and 7:00 PM EST on Nov 14 (financial)."],"consensus_eps_estimate":null,"consensus_eps_actual":0.01,"consensus_revenue_estimate":null,"consensus_revenue_actual":76532801.0,"consensus_period":"2026-Q2","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":369302084.06008106,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":117095,"accession_number":"0001493152-25-021392","cik":1053369,"company_name":"ELITE PHARMACEUTICALS INC /NV/","ticker":"ELTP","form_type":"8-K","filed_at":"2025-11-10T23:59:59+00:00","items":["7.01","2.02","9.01"],"status":"ready","headline":"Elite Pharma to release Q2 FY2026 results Nov 14; conference call Nov 17","summary_kind":"llm","event_type":"other_material","confidence":"medium","bullets":["Q2 FY2026 financial results (ended Sep 30, 2025) to be released on Friday, November 14, 2025.","Management conference call set for Monday, November 17, 2025, at 11:30 AM EST.","Dial-in numbers: 1-800-346-7359 (domestic), 1-973-528-0008 (international); conference ID 98840.","Stockholder questions accepted via email (dianne@elitepharma.com) by deadlines listed in release."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.2,"market_cap_usd":369302084.06008106,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":133548,"accession_number":"0001641172-25-024088","cik":1053369,"company_name":"ELITE PHARMACEUTICALS INC /NV/","ticker":"ELTP","form_type":"8-K","filed_at":"2025-08-14T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"Elite Q1 revenue $40.2M, up 114% YoY; operating profit $21.7M, up 462%","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Consolidated revenues of $40.2M for Q1 FY2026, a 114% increase YoY from the prior year comparable period.","Operating profits of $21.7M, a 462% increase YoY, driven by sales of lisdexamfetamine products and strong Elite label growth.","Lisdexamfetamine products launched after the prior year Q1, contributing significantly to the top-line expansion.","Company will host a conference call on August 15, 2025 at 11:30 AM EDT to discuss results and provide a business update."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.01,"consensus_revenue_estimate":null,"consensus_revenue_actual":40211097.0,"consensus_period":"2026-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":369302084.06008106,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":133547,"accession_number":"0001493152-25-011765","cik":1053369,"company_name":"ELITE PHARMACEUTICALS INC /NV/","ticker":"ELTP","form_type":"8-K","filed_at":"2025-08-08T23:59:59+00:00","items":["7.01","2.02","9.01"],"status":"ready","headline":"Elite Pharmaceuticals announces Q1 FY2026 results release on Aug 14, conference call Aug 15","summary_kind":"llm","event_type":"other_material","confidence":"low","bullets":["Financial results for Q1 FY2026 (ended June 30, 2025) to be released August 14, 2025.","Conference call to discuss results and provide corporate update on August 15, 2025 at 11:30 AM EDT.","Dial-in: 1-800-346-7359 (domestic) or 1-973-528-0008 (intl), conference ID 98840.","Stockholders can submit questions by email to dianne@elitepharma.com by deadlines: general by Aug 13, financial by Aug 14."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.2,"market_cap_usd":369302084.06008106,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":150223,"accession_number":"0001641172-25-017151","cik":1053369,"company_name":"ELITE PHARMACEUTICALS INC /NV/","ticker":"ELTP","form_type":"8-K","filed_at":"2025-06-30T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"Elite Pharma FY2025 revenue $84.0M (+48% YoY); operating profit $19.6M (+81% YoY)","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Consolidated revenue for FY2025 (ended March 31, 2025) was $84.0M, up 48% from $56.6M prior year.","Operating profit rose 81% to $19.6M, driven by lisdexamfetamine products launched in FY2025 and Elite label product lines.","Conference call scheduled for July 1, 2025 at 11:30 AM EDT to discuss results and business update.","Company requests stockholder questions be submitted by 7:00 PM EDT on June 30, 2025.","No EPS or net income figures disclosed in the press release; full 10-K filed separately."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.01,"consensus_revenue_estimate":null,"consensus_revenue_actual":40211097.0,"consensus_period":"2026-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":369302084.06008106,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":150222,"accession_number":"0001641172-25-016000","cik":1053369,"company_name":"ELITE PHARMACEUTICALS INC /NV/","ticker":"ELTP","form_type":"8-K","filed_at":"2025-06-23T23:59:59+00:00","items":["7.01","2.02","9.01"],"status":"ready","headline":"Elite Pharmaceuticals to report FY2025 results June 30, host call July 1","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["FY2025 (ended March 31, 2025) financial results to be released June 30, 2025.","Conference call to discuss results on July 1, 2025 at 11:30 AM EDT.","Dial-in: 1-800-346-7359 (domestic) or 1-973-528-0008 (international); ID 98840.","Shareholders can email questions to dianne@elitepharma.com by respective deadlines."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.2,"market_cap_usd":369302084.06008106,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":150221,"accession_number":"0001641172-25-015172","cik":1053369,"company_name":"ELITE PHARMACEUTICALS INC /NV/","ticker":"ELTP","form_type":"8-K","filed_at":"2025-06-16T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Elite Pharma reports positive bioequivalence study for undisclosed anticoagulant generic; brand sales $27B","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Positive pivotal bioequivalence results for an undisclosed generic anticoagulant; product is bioequivalent to brand.","Branded product sales $27B (12 months ending April 2025); no generic marketed; unexpired Orange Book patent exists.","Elite will compile data to file ANDA with FDA; commercialization conditional on FDA approval and patent resolution."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":369302084.06008106,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":150220,"accession_number":"0001641172-25-007836","cik":1053369,"company_name":"ELITE PHARMACEUTICALS INC /NV/","ticker":"ELTP","form_type":"8-K","filed_at":"2025-04-30T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Elite launches generic Percocet (oxycodone/acetaminophen) tablets in 3 strengths","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Launched generic oxycodone HCl/acetaminophen tablets in 5/325, 7.5/325, and 10/325 mg strengths.","Product is indicated for moderate to moderately severe pain, marketed under Elite Laboratories label.","IQVIA reported 2024 brand sales of ~$317 million for the reference product."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":369302084.06008106,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":169224,"accession_number":"0001493152-25-008808","cik":1053369,"company_name":"ELITE PHARMACEUTICALS INC /NV/","ticker":"ELTP","form_type":"8-K","filed_at":"2025-03-03T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Elite Pharmaceuticals ships first product from new FDA-approved expanded campus","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["First lot of finished product shipped from new facility at 144 Ludlow Avenue, Northvale, NJ.","New packaging line runs at ~120 bottles per minute, adding packaging, inventory and warehouse space.","Expansion converts existing packaging space into additional manufacturing suites, boosting production capacity.","Company says new facility positions it to meet projected packaging demand for at least the next five years."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":369302084.06008106,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":169223,"accession_number":"0001493152-25-006471","cik":1053369,"company_name":"ELITE PHARMACEUTICALS INC /NV/","ticker":"ELTP","form_type":"8-K","filed_at":"2025-02-13T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"Elite Pharma Q3 fiscal 2025 revenue $14.4M (-8% YoY); operating profit $1.1M (-69%)","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Consolidated revenue $14.4M for quarter ended Dec 31, 2024, down 8% from $15.6M in prior-year period.","Operating profit fell 69% to $1.1M from $3.5M; company cites year-end holiday shipment delays.","Shipments delayed into first week of January 2025 due to timing differences at December holiday period.","No EPS, net income, or updated guidance provided in the release; conference call scheduled Feb 14."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.02,"consensus_revenue_estimate":null,"consensus_revenue_actual":52047656.0,"consensus_period":"2025-Q3","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":369302084.06008106,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":186265,"accession_number":"0001493152-24-052104","cik":1053369,"company_name":"ELITE PHARMACEUTICALS INC /NV/","ticker":"ELTP","form_type":"8-K","filed_at":"2024-12-26T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Elite Launches Generic Vyvanse (Lisdexamfetamine) in 7 Strengths for ADHD","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Elite launched generic lisdexamfetamine (Vyvanse) in 10, 20, 30, 40, 50, 60, 70 mg capsules.","Branded Vyvanse annual sales ~$4.3B (12 months ending Oct 2024, per IQVIA).","Product marketed under Elite Laboratories label; company operates cGMP/DEA facility in Northvale, NJ.","This generic version is indicated for treatment of attention deficit hyperactivity disorder (ADHD).","Launch represents expansion of Elite's niche generic product portfolio."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":369302084.06008106,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":186264,"accession_number":"0001493152-24-048294","cik":1053369,"company_name":"ELITE PHARMACEUTICALS INC /NV/","ticker":"ELTP","form_type":"8-K","filed_at":"2024-12-02T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Elite Pharmaceuticals launches generic Norco (hydrocodone/acetaminophen) tablets","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Launched generic Norco (hydrocodone bitartrate/acetaminophen) in 2.5/325, 5/325, 7.5/325, and 10/325 mg strengths.","Indicated for management of pain severe enough to require an opioid analgesic when alternatives are inadequate.","IQVIA reported annual sales of approximately $300M for the brand product for 12 months ending September 2024.","Product marketed and sold under the Elite Laboratories label."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":369302084.06008106,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":186263,"accession_number":"0001493152-24-046525","cik":1053369,"company_name":"ELITE PHARMACEUTICALS INC /NV/","ticker":"ELTP","form_type":"8-K","filed_at":"2024-11-18T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Elite Pharma gets FDA nod for generic Vyvanse; $4.3B market","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Received FDA approval on November 15, 2024 for ANDA for generic Lisdexamfetamine Dimesylate (Vyvanse) in 7 strengths (10-70 mg capsules).","Product indicated for ADHD; marketed under Elite Laboratories label.","IQVIA reported annual sales of $4.3B for brand and generic market (12 months ending September 2024)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":369302084.06008106,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":186262,"accession_number":"0001493152-24-046001","cik":1053369,"company_name":"ELITE PHARMACEUTICALS INC /NV/","ticker":"ELTP","form_type":"8-K","filed_at":"2024-11-14T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"Elite Pharma Q2 FY2025 revenue $18.9M (+33% YoY); operating profit $3.5M (+84%)","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Consolidated revenue $18.9M for Q2 ended Sep 30, 2024, up $4.7M or 33% vs prior year.","Operating profit $3.5M, up $1.6M or 84% YoY, driven by higher Elite label product sales.","Conference call scheduled for Nov 15, 2024 at 11:30 AM EST to discuss results and business update.","Stockholders can submit financial questions by 7 PM EST on Nov 14 via dianne@elitepharma.com."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.01,"consensus_revenue_estimate":null,"consensus_revenue_actual":37683408.0,"consensus_period":"2025-Q2","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":369302084.06008106,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":186261,"accession_number":"0001493152-24-040752","cik":1053369,"company_name":"ELITE PHARMACEUTICALS INC /NV/","ticker":"ELTP","form_type":"8-K","filed_at":"2024-10-10T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Israeli Ministry of Health approves Elite's generic Adderall; first shipment months away","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Israeli Ministry of Health approved Elite's generic Adderall (mixed amphetamine salts) in 10mg, 20mg, 30mg tablets on Oct 7, 2024.","Elite will supply to exclusive distributor Dexcel Pharma for the Israeli market; Dexcel handles sales/marketing at its expense.","Product jointly owned by Elite and Mikah Pharma; first shipment depends on licensee orders, DEA quotas, and manufacturing.","Under license agreement, Dexcel pays transfer price and shares profits under certain conditions."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":369302084.06008106,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":186260,"accession_number":"0001493152-24-040288","cik":1053369,"company_name":"ELITE PHARMACEUTICALS INC /NV/","ticker":"ELTP","form_type":"8-K","filed_at":"2024-10-07T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Elite Pharmaceuticals launches generic Tylenol with Codeine tablets across three strengths","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Launched generic acetaminophen/codeine phosphate tablets in 300mg/15mg, 300mg/30mg, 300mg/60mg.","Product marketed under Elite Laboratories label for mild to moderate pain management.","US market for these tablets approximated $47M for 12 months ended May 2024 (IQVIA).","Launch expands Elite's niche generic portfolio; company operates cGMP/DEA facility in Northvale, NJ."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":369302084.06008106,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":202892,"accession_number":"0001493152-24-034019","cik":1053369,"company_name":"ELITE PHARMACEUTICALS INC /NV/","ticker":"ELTP","form_type":"8-K","filed_at":"2024-08-27T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Elite Pharmaceuticals launches generic methotrexate sodium 2.5 mg tablets","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Product launched for ALL, mycosis fungoides, non-Hodgkin's lymphoma, rheumatoid arthritis, severe psoriasis, pJIA.","Total US market for methotrexate sodium 2.5 mg tablets was ~$63M (12 months ended May 2024, IQVIA).","Marketed under Elite Laboratories, Inc. label; DEA/cGMP facility in Northvale, NJ.","Elite (OTCQB: ELTP) develops and manufactures niche generic products."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":369302084.06008106,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":202891,"accession_number":"0001493152-24-032412","cik":1053369,"company_name":"ELITE PHARMACEUTICALS INC /NV/","ticker":"ELTP","form_type":"8-K","filed_at":"2024-08-14T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"Elite Pharma Q1 FY2025 revenue up 109% YoY to $18.8M; operating profit +144%","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue of $18.8M for Q1 ended June 30, 2024, compared to $9.0M in Q1 FY2024.","Operating profit rose to $3.9M from $1.6M YoY, a 144% increase.","Net income attributable to common shareholders was $0.6M.","Growth driven by higher sales of Elite label product line.","Conference call scheduled for August 15, 2024 at 11:30 AM EDT."],"consensus_eps_estimate":null,"consensus_eps_actual":0.0,"consensus_revenue_estimate":null,"consensus_revenue_actual":18803063.0,"consensus_period":"2025-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":369302084.06008106,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":202890,"accession_number":"0001493152-24-025848","cik":1053369,"company_name":"ELITE PHARMACEUTICALS INC /NV/","ticker":"ELTP","form_type":"8-K","filed_at":"2024-07-01T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"Elite Pharma FY2024 revenue $56.6M (+65% YoY); operating profit $10.8M (+192%)","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue of $56.6M, up $22.4M (65%) from prior fiscal year.","Operating profit $10.8M, up $7.1M (192%) YoY.","Net income attributable to common shareholders was $20.1M.","Growth driven by commercial launch of Elite label product line in FY2024.","Conference call on July 2, 2024 at 11:30 AM EDT for business update."],"consensus_eps_estimate":null,"consensus_eps_actual":0.0,"consensus_revenue_estimate":null,"consensus_revenue_actual":18803063.0,"consensus_period":"2025-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":369302084.06008106,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":219089,"accession_number":"0001493152-24-024720","cik":1053369,"company_name":"ELITE PHARMACEUTICALS INC /NV/","ticker":"ELTP","form_type":"8-K","filed_at":"2024-06-21T23:59:59+00:00","items":["1.01"],"status":"ready","headline":"Elite Pharmaceuticals acquires three ANDAs from Nostrum Laboratories for $900k","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Acquired ANDAs for generic Norco (hydrocodone/APAP), Percocet (oxycodone/APAP), and Dolophine (methadone) from Nostrum.","Paid $900,000 cash; also received royalty-free perpetual license for manufacturing technology.","Asset Purchase Agreement signed June 17, 2024; transaction closed June 21, 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":369302084.06008106,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":219088,"accession_number":"0001493152-24-022732","cik":1053369,"company_name":"ELITE PHARMACEUTICALS INC /NV/","ticker":"ELTP","form_type":"8-K","filed_at":"2024-06-05T23:59:59+00:00","items":["4.01","9.01"],"status":"ready","headline":"Elite Pharmaceuticals replaces auditor: Mazars USA succeeded by Forvis Mazars, LLP after Mazars USA merger","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Mazars USA resigned as auditor effective June 1, 2024, as substantially all partners/employees joined Forvis, LLP (renamed Forvis Mazars, LLP).","Forvis Mazars appointed as new independent registered public accounting firm, effective same date, approved by Audit Committee and Board.","No disagreements or reportable events between company and Mazars USA during past two fiscal years and interim period.","No prior consultations with Forvis Mazars regarding accounting principles or audit opinions before appointment."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":369302084.06008106,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":219087,"accession_number":"0001493152-24-020707","cik":1053369,"company_name":"ELITE PHARMACEUTICALS INC /NV/","ticker":"ELTP","form_type":"8-K","filed_at":"2024-05-20T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Elite Pharma receives FDA approval for generic Methotrexate; market $64.3M annual sales","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["FDA approved ANDA for generic Methotrexate Sodium 2.5 mg tablets on May 16, 2024.","Product will be marketed under Elite Laboratories, Inc. label.","IQVIA reports $64.3 million in annual U.S. generic market sales (12 months ending Mar 2024)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":369302084.06008106,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":238967,"accession_number":"0001493152-24-006722","cik":1053369,"company_name":"ELITE PHARMACEUTICALS INC /NV/","ticker":"ELTP","form_type":"8-K","filed_at":"2024-02-14T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"Elite Pharma Q3 revenue up 68% to $15.5M; operating profit up 80% to $3.5M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $15.5M for Q3 FY2024 ended Dec 31, 2023, +68% YoY from $9.2M.","Operating profit $3.5M, +80% YoY from $1.9M.","Growth attributable to sales of Elite Laboratories label products launched during FY2024.","Company to hold conference call Feb 15, 2024 at 11:30 AM EST."],"consensus_eps_estimate":null,"consensus_eps_actual":0.02,"consensus_revenue_estimate":null,"consensus_revenue_actual":38676061.0,"consensus_period":"2024-Q3","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":369302084.06008106,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":256456,"accession_number":"0001493152-23-046142","cik":1053369,"company_name":"ELITE PHARMACEUTICALS INC /NV/","ticker":"ELTP","form_type":"8-K","filed_at":"2023-12-26T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Elite Pharmaceuticals files ANDA for generic CNS stimulant; market $5.1B","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["ANDA accepted for review by FDA on Dec 21, 2023 for undisclosed generic CNS stimulant.","IQVIA reports annual brand and generic market sales of $5.1B for this product (12 months to June 2023).","Elite operates a cGMP and DEA-registered facility in Northvale, NJ for R&D and manufacturing.","No launch timeline or revenue guidance provided; approval and commercialization still pending."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":369302084.06008106,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":256455,"accession_number":"0001493152-23-044556","cik":1053369,"company_name":"ELITE PHARMACEUTICALS INC /NV/","ticker":"ELTP","form_type":"8-K","filed_at":"2023-12-12T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Elite Pharmaceuticals ships first order of generic Adderall XR to distributor Prasco","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["First shipment of generic Adderall XR (5-30 mg extended-release amphetamine capsules) to Prasco, LLC.","Shipment under non-exclusive Mfg, Supply & Distribution Agreement dated April 5, 2023; Prasco markets under Burel label.","Product co-owned with Mikah Pharma; financial terms not disclosed."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":369302084.06008106,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":256454,"accession_number":"0001493152-23-041323","cik":1053369,"company_name":"ELITE PHARMACEUTICALS INC /NV/","ticker":"ELTP","form_type":"8-K","filed_at":"2023-11-14T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"Elite Pharma Q2 FY2024 revenue $14.2M (+64.9% YoY); net income $14.9M (+886%)","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Consolidated revenue of $14.2M for Q2 ended Sep 30, 2023, up 64.9% YoY.","Operating profit of $1.9M, up 78.1% from prior-year period.","Net income attributable to common shareholders: $14.9M, an 886% increase.","Growth driven by launch of Elite Laboratories label product line in June 2023 quarter.","Conference call scheduled for Nov 15, 2023 at 11:30 AM EST."],"consensus_eps_estimate":null,"consensus_eps_actual":0.02,"consensus_revenue_estimate":null,"consensus_revenue_actual":23137261.0,"consensus_period":"2024-Q2","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":369302084.06008106,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":273852,"accession_number":"0001493152-23-033590","cik":1053369,"company_name":"ELITE PHARMACEUTICALS INC /NV/","ticker":"ELTP","form_type":"8-K","filed_at":"2023-09-25T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Elite Pharmaceuticals files ANDA for generic opiate analgesic with $720M market","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Filed ANDA with FDA on August 17, 2023 for a generic opiate analgesic product.","FDA accepted the ANDA for review on September 19, 2023.","IQVIA reported $720 million in annual brand and generic sales for this product (12 months ending June 2023).","The specific drug product remains undisclosed."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":369302084.06008106,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":273851,"accession_number":"0001493152-23-031972","cik":1053369,"company_name":"ELITE PHARMACEUTICALS INC /NV/","ticker":"ELTP","form_type":"8-K","filed_at":"2023-09-07T23:59:59+00:00","items":["1.01","5.02","9.01"],"status":"ready","headline":"Elite Pharmaceuticals reappoints Carter Ward as CFO effective Sept 5, 2023","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Carter Ward reappointed CFO, secretary, treasurer; previously served from July 2009 to May 2021.","Base salary $275,000; guaranteed annual bonus 20% of base; performance bonus up to 30%.","Granted options to purchase 3,000,000 shares at closing price on effective date.","Severance: 2 months salary per year of service (max 12 months) if terminated without cause or for good reason."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":369302084.06008106,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":273850,"accession_number":"0001493152-23-028684","cik":1053369,"company_name":"ELITE PHARMACEUTICALS INC /NV/","ticker":"ELTP","form_type":"8-K","filed_at":"2023-08-14T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"Elite Pharma Q1 revenue up 17% to $9.0M; net income up 267% to $1.1M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $9.0M (+16.9% YoY); operating profit $1.6M (+60% YoY).","Net income attributable to common shareholders $1.1M (+267% YoY).","Growth driven by launch of Elite Laboratories label product line."],"consensus_eps_estimate":null,"consensus_eps_actual":0.0,"consensus_revenue_estimate":null,"consensus_revenue_actual":8980076.0,"consensus_period":"2024-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":369302084.06008106,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":273849,"accession_number":"0001493152-23-024726","cik":1053369,"company_name":"ELITE PHARMACEUTICALS INC /NV/","ticker":"ELTP","form_type":"8-K","filed_at":"2023-07-17T23:59:59+00:00","items":["4.01","9.01"],"status":"ready","headline":"Elite Pharmaceuticals dismisses Buchbinder, appoints Mazers as new auditor","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Audit Committee approved appointment of Mazers USA LLP on July 11, 2023, effective same day.","Buchbinder Tunick & Company LLP was dismissed as independent auditor, effective July 12, 2023.","No disagreements or reportable events with Buchbinder during fiscal years 2022 and 2023 or subsequent interim period.","Buchbinder's reports for those fiscal years contained no adverse opinion or qualification."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.35,"calibrated_materiality_score":0.35,"market_cap_usd":369302084.06008106,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":290939,"accession_number":"0001493152-23-022959","cik":1053369,"company_name":"ELITE PHARMACEUTICALS INC /NV/","ticker":"ELTP","form_type":"8-K","filed_at":"2023-06-29T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"Elite Pharma FY2023 revenue $34.2M (+5.9% YoY); operating profit down $1.4M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["FY2023 revenues $34.2M, up 5.9% from prior year; net income $3.6M.","Operating profit $3.7M, a decrease of $1.4M due to higher R&D and sales-distribution investment.","Company will host conference call June 30 at 11:30 AM EDT to discuss results.","Stockholder questions accepted via email prior to the call."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":369302084.06008106,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":290938,"accession_number":"0001493152-23-015304","cik":1053369,"company_name":"ELITE PHARMACEUTICALS INC /NV/","ticker":"ELTP","form_type":"8-K","filed_at":"2023-05-03T23:59:59+00:00","items":["1.01","5.02","9.01"],"status":"ready","headline":"Elite Pharmaceuticals appoints Mark Pellegrino as CFO effective May 1, 2023","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Mark Pellegrino appointed CFO, replacing Robert Chen, effective May 1, 2023.","Annual base salary of $230,000; eligible for 1.5M stock options vesting over 3 years.","Pellegrino has 30+ years of life sciences finance experience, most recently consultant at Barbera & Barbera.","Stock option strike price set at closing price on first day of employment (ELTP)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":369302084.06008106,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":290937,"accession_number":"0001493152-23-013037","cik":1053369,"company_name":"ELITE PHARMACEUTICALS INC /NV/","ticker":"ELTP","form_type":"8-K","filed_at":"2023-04-20T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Elite Pharmaceuticals files ANDA for generic antimetabolite; $42M market","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Filed Abbreviated New Drug Application with FDA for an undisclosed generic antimetabolite drug.","IQVIA reports annual sales of $42M for the generic market of this product (12 months ending Dec 2022).","Elite is a specialty pharma developing niche generics; facility in Northvale, NJ."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":369302084.06008106,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":null}